ECTRIMS 2021 | Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD

Bruce Cree, MD, PhD, MAS, University of California San Francisco, San Francisco, CA, discusses the design and findings of N-MOmentum (NCT02200770), a randomized double-blind placebo-controlled study evaluating the safety and efficacy of inebilizumab in aquaporin-4 immunoglobulin G antibodies (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD). The primary endpoint was the time to first confirmed neuromyelitis optica attack. In this study, patients were randomized 3:1 to inebilizumab monotherapy or placebo for 28 weeks or up to attack occurrence, after which they were offered entry to an open-label extension which lasted approximately five years. The trial demonstrated that attack frequency decreased with each subsequent year of treatment, thereby suggesting that therapeutic benefit improves over time. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.